孙建博博士，91porn 天然药物化学系教授，博导，中药学本科专业负责人。入选江苏省六大人才高峰高层次人才，江苏省333计划高层次人才。博士毕业于91porn ，美国威斯康星大学-麦迪逊分校访问学者。教学案例入选2024年江苏省教育数字化十大创新案例，并获得2025年江苏省教学创新大赛一等奖。

科研团队通过深入的靶配分析、功能性验证以及机制探讨，综合应用分子芯片筛选、Alphafold3等配体筛选平台及快速的药物高通量合成模式，主导免疫活化、抗抑郁等药物的设计及膜转运蛋白的功能性配体发现。在Journal of the American Chemical Society,Trends in Pharmacological Sciences, Acta Pharmaceutica Sinica B，Journal of Medicinal Chemistry等共发表SCI论文60余篇，18项专利授权。主持国自然基金、省基金及企业横向课题20余项。

在校企合作中，团队擅长以产业需求为导向组织联合攻关，依托高校平台与企业共建联合实验室，推动技术从研发验证到产品化落地，并注重以功效研究与安全性评价等证据链支撑成果转化。已与薇美姿集团、香百年集团及南京宁丹新药等企业开展合作，形成功能性食品、口腔植萃、功能性香薰与新药技术等多方向布局。研发的舒客植萃护龈牙膏、防晕车、抗疲劳车载空调嵌合模块、奥普恒流美容灯等项目已成功上市，合作经费累计约900万元。1项抗抑郁检测试剂盒已实现临床转化，对重度抑郁症的诊断准确度达到92.6%，并可对抑郁症进行发病机制分型，以实现对抑郁症的精准医疗，目前已进入全国250家医院。

天然药物化学，波谱解析

[1] Zhou Xin-Yue^#, Xu Zhongyuan^#, Liu Xiwen^#, Wu Guiying, Hou Yudong, Qi Lian-Wen^*, Liu Qun^*, Sun Jianbo^*. Bifunctional LYTAC Mediates Hepatocytes-Hepatic Stellate Cells Crosstalk by Regulating 5HT2A Receptor Degradation and Antagonism to Synergistically Ameliorate Hepatic Fibrosis.J Am Chem Soc (IF: 15.7), 2025, 147(48): 44162-44174.

[2] Wang Menghua^#, Takudzwa Chiwoneso^#, Luo Zimeng^#, Justice Josiah Mallen, Xia Yuanzheng^*, Sun Jianbo^*. Cancer Pathogenesis and Phase Targeting through Condensate Fragility. Trends in Pharmacological Sciences(IF: 19.9), 2026, s0165-6147(26)00015-5.

[3] Peisen Zhong^#, Xinyu Mao^#, Na Li^#, Li Chen^*, andJianbo Sun^*. Development of Nitric Oxide Releasing Oxoisoaporphines with Antidepressant Activities by Simultaneously Regulating MAOA and SERT.J Med Chem, 2024, 67, 15509-15520.

[4] Qi Mingming^#, Zhong Hui^#, Cheng Zhaoyan^#, Chen Shujie, Xiao Han, Shang Jing, Chen Li^*, Sun Jianbo^*.Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1. J Med Chem, 2023, 66, 13, 9184-9200.

[5] Wang Kun^#, Zhong Hui^#, Li Na,Yu Nairong, Wang Yujin, Chen Li^*, Sun Jianbo^*. Discovery of Novel Anti-Breast-Cancer Inhibitors by SynergisticallyAntagonizing Microtubule Polymerization and Aryl Hydrocarbon ReceptorExpression, J Med Chem, 2021, 64, 12964-12977.

[6] Sun Xiaona^#, Li Na^#, Zhong Peisen, Chen Li^*, Sun Jianbo^*. Development of MAO-A and 5-HT2AR Dual Inhibitors with Improved Antidepressant Activity, J Med Chem, 2022, 65(19): 13385-13400.

[7] Li Na^#, Xu Manyi^#, Zhang Lulu, Lei Zhichao, Chen Cheng, Zhang Tianyuan, Chen Li^*,Sun Jianbo^*. Discovery of Novel Celastrol-Imidazole Derivatives with Anticancer Activity In Vitro and In Vivo, J Med Chem, 2022, (65): 4578-4589.

[8] Sun Jianbo^#, Zhong Hui^#, Wang Kun, Li Na^*, Chen Li^*.Gains from no Real PAINS: Where ‘Fair Trial Strategy’ Stands in the Developmentof Multi-target Ligands. Acta Pharm Sin B. 2021, 11(11): 3417-3432.